SynthesisWideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques2025
Transarterial chemoembolization with 125 I seed insertion for unresectable hepatocellular carcinoma: a meta‑analysis.
Synthesis in Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transarterial chemoembolization with radioactive seed implantation for multitumor hepatocellular carcinoma.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2026Article
- High conversion rate and survival benefits of transarterial chemoembolization with targeted immunotherapy in initially unresectable hepatocellular carcinoma: efficacy, safety, and optimal patient selection.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransarterial chemoembolization (TACE) is frequently used to treat patients with hepa‑ tocellular cancer (HCC) who are not eligible for surgery. The efficacy of TACE treatment can be improved by percutaneous insertion of 125I seeds after the procedure.
aimThis meta‑analysis aimed to assess the relative safety and efficacy of TACE with 125I seed insertion (TACE‑I) as compared with TACE alone for the management of inoperable HCC. MATERIALS AND
methodsThe PubMed, Cochrane Library, and Wanfang databases were searched for relevant studies published since the database inception through October 2024. The primary study outcome was objective response rate (ORR), while secondary outcomes comprised disease control rate (DCR), progression‑free survival (PFS), overall survival (OS), and adverse event incidence.
resultsThis meta‑analysis ultimately included 5 articles, all of which were published in China. In all these studies, TACE‑I outperformed TACE alone with respect to patient ORR (P <0.001), PFS (P <0.001), and OS (P <0.001). DCR values were similar in both groups (P = 0.77), as were the rates of adverse events, including fever (P = 0.75), vomiting (P = 0.83), and myelosuppression (P = 0.23). The only outcome exhibiting significant heterogeneity was OS (I2 = 73%). Based on the Egger test, the end points affected by publication bias were ORR, DCR, and OS (P = 0.01, P = 0.03, and P = 0.04, respectively).
conclusionsIn patients with inoperable HCC, TACE‑I is associated with significantly better efficacy and longer survival than TACE alone, and has a good safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.